Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024
-A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in trials conducted in the U.S. and Japan Pivotal U.S. Phase 3 study results published in The Spine Journal About nine million adults in the U.S. suffer from lumbar disc herniation each year Parsippany, NJ – September 25, 2024 – Ferring Pharmaceuticals […]
-
Ferring to Present New Data Analysis at NASS 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
-Parsippany, NJ – September 9, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced they will be presenting an analysis of data at the North American Spine Society’s (NASS) Annual Meeting from two Phase 3 trials for SI-6603, an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation […]
-
Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024
-A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 with notable differences observed as early as Week 4 No treatment-related serious adverse events occurred with SI-6603 Additional analysis presented at ASPN evaluated economic burden of lumbar disc herniation surgery Parsippany, NJ – July 15, 2024 – Ferring Pharmaceuticals and its clinical […]